Certriad

Treatment for Hyperlipidemia, Hypertriglyceridemia, Hyperlipoproteinemia

Abbott and AstraZeneca End License Agreement for the Development of Certriad

ABBOTT PARK, Ill., Dec. 22, 2010 /PRNewswire-FirstCall/ -- Abbott announced today that Abbott and AstraZeneca will discontinue their joint collaboration for the development of Certriad (rosuvastatin / fenofibric acid delayed release) Capsules. The companies reached this decision after careful consideration of the Complete Response Letter received from the U.S. Food and Drug Administration, the resulting regulatory delay and the commercial attractiveness of the product in the U.S. market.

There will be no financial impact to Abbott's ongoing earnings per share in 2010 or 2011 resulting from this action.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

SOURCE Abbott

CONTACT: Media, Elizabeth Hoff, +1-847-935-4236, or Financial, Larry Peepo, +1-847-935-6722, both of Abbott


Web Site: http://www.abbott.com

Posted: December 2010

Related Articles

Certriad (rosuvastatin calcium and fenofibric acid) FDA Approval History

View comments

Hide
(web3)